# Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

> **NCT02728102** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 203 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **PROCEDURE:** Tumor Cell Collection
- **PROCEDURE:** Autologous Stem Cell Transplant
- **DRUG:** Melphalan
- **PROCEDURE:** Leukapheresis
- **BIOLOGICAL:** Myeloma vaccine
- **DRUG:** GM-CSF
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02728102
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2020-06-30
- **Final completion:** 2022-12-09
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2024-05-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02728102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02728102, "Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02728102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*